news

MSD investment confirms thriving biopharmaceutical hub

MSD to invest €280 million in Ireland over the next three years bolsters the country’s status as a thriving hub for the biopharmaceutical sector…

Double Helix

BioPharmaChem Ireland, the Ibec group that represents business in the sector, said the announcement of MSD to invest €280 million in Ireland over the next three years bolsters the country’s status as a thriving hub for the biopharmaceutical sector.

Director of BioPharmaChem Ireland Matt Moran said: “The biopharma industry in Ireland champions innovation, with over 25,000 talented people within the industry in Ireland delivering ground-breaking solutions to patients both here and globally.

The announcement from MSD to create up to 330 new jobs at their Irish sites demonstrates its position at the heart of the corporation’s new products and at the cutting edge of biopharmaceutical innovation.

“It is the mission of the industry in Ireland to continue to support discovery and innovation in the manufacture of life-changing medicines, and to remain the global location of choice for the development and manufacture of biopharmaceuticals,” concluded Mr Moran.

Related organisations

,

Send this to a friend